Physical exercise is accepted as an effective treatment method to improve muscle strength, physical fitness, and walking capacity. Evidence is robust for standardized endurance and resistance training programs in ambulatory persons with relapsing remitting multiple sclerosis (MS), with indications of beneficial effects in progressive type of MS. However, few studies have been performed in severely affected patients requiring at least unilateral support during walking. It is obviously more difficult to reach high-intensity training when motor dysfunction is pronounced and symptoms such as impaired balance and motor fatigability are present. 1 The treatment potential and best modality in severely disabled patients are not yet established.
Robot-assisted therapy could be a promising treatment modality as it facilitates the provision of highintensity and repetitive movement training in disabled patients. Robot-assisted gait training (RAGT) was consistently shown to be feasible and well accepted in persons with not only stroke but also MS, probably because of the sense of achievement in contrast to failure in daily life physical functioning. RAGT studies in MS, with one exception, applied the Lokomat, which is an exoskeleton robot that is actively driving knee, hip, and trunk movements mimicking a normal symmetrical gait pattern. [2] [3] [4] Importantly, positive effects of RAGT on balance and gait speed were found, indicating treatment potential in severely disabled patients. However, the superiority of RAGT compared to conventional walking or balance training is unclear. Inconsistent findings in previous studies may relate to the severity of ambulatory dysfunction in those recruited. In stroke, RAGT is recommended in patients who cannot walk independently. 5 In this context, the randomized controlled trial by Straudi et al. 6 is timely as it selected exclusively persons with the progressive type of MS with high disability (expanded disability status scale (EDSS) 6-7), indicating dependency on walking aids. In fact, participants walked only 0.52 m/s on average, indicating that they were so-called most limited community walkers. The effects of 6 weeks of RAGT were compared to a conventional balance and walking training program. Both treatment modalities affected nonmotor functions, such as depression, positively. Within the physical domain, no effects were found on short timed tests for walking speed (10-meter walk test (10MWT)) or functional mobility (timed up and go (TUG)). However, RAGT was shown to be superior for improving walking distance measured by the 6-minute walk test (6MWT), leading to the hypothesis that its working mechanisms are related to physical fitness and muscle endurance rather than maximal muscle strength. Interestingly, Straudi et al. 6 also revealed that improvements increased gradually over time (6 vs 3 weeks of training), indicating that severely disabled patients with progressive MS may need a longer period of training stimulus in order to reach a plateau of maximal effect. Unfortunately, effects were not retained at 3-month follow-up, emphasizing the need for continued treatment rather than short-term intervention.
Robots and electro-mechanical devices also exist to assist or challenge goal-directed upper limb movements, within engaging virtual learning environments. Robot-assisted upper limb therapy is increasingly being investigated in MS, demonstrating improved motor coordination, movement amplitude, and grip function in persons with cerebellar problems and severe upper limb dysfunction. 7, 8 Qualitatively, patients report on improved stability in holding daily life objects in their hands or better performance in upper limb activities such as eating much longer, possibly indicating improved muscle endurance. 9 Although positive effects on gait and upper limb function have been demonstrated, caution is needed before there is widespread implementation of robot therapy. First, definite trials in large samples, as performed for the upper limb in stroke, 10 are needed. An understanding of the dosage-related treatment effect over time needs clarification. Second, the health economics needs to be considered. Robots come with a high purchase cost, and considerable therapist time is needed to help the disabled patient to get connected with the robot and to program the required difficulty level. Third, robots need further technological development which includes the rehabilitation therapist's perspective of task-oriented training and motor learning, in order to relate more close to daily life mobility and upper limb use. For example, the robotic device applied in Straudi et al.'s study mainly applies a symmetrical gait pattern with the patient being secured by trunk fixation and body weight support. This may insufficiently challenge the patient regarding balance and motor adaptations required to the outside environment. Finally, robot therapy may be complimented by low-cost sensor-based therapies to enlarge therapy volume and sustain training over longer time.
